Genomic Characterization of Primary Invasive Lobular Breast Cancer [Breast Cancer]
Conclusion
This study demonstrates that we can now begin to individualize the treatment of ILBC, with HER2, HER3, and AKT1 mutations representing high-prevalence therapeutic targets and FOXA1 mutations and ESR1 gains deserving urgent dedicated clinical investigation, especially in the context of endocrine treatment.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Desmedt, Zoppoli, Gundem, Pruneri, Larsimont, Fornili, Fumagalli, Brown, Rothe, Vincent, Kheddoumi, Rouas, Majjaj, Brohee, Van Loo, Maisonneuve, Salgado, Van Brussel, Lambrechts, Bose, Metzger, Galant, Bertucci, Piccart-Gebhart, Viale, Biganzoli, Campbell Tags: Translational Oncology, Breast Cancer, Cancer Biomarkers, Oncogenes Source Type: research